Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -4.16%15.96B | -14.42%3.31B | -6.93%5.33B | 7.18%3.95B | -0.07%3.37B | 4.57%16.65B | 0.43%3.87B | 12.41%5.72B | -1.30%3.68B | 3.95%3.37B |
Cost of revenue | -1.77%10.32B | -15.00%2.24B | -3.20%3.42B | 10.01%2.51B | 4.60%2.15B | 15.95%10.51B | 11.94%2.64B | 22.34%3.53B | 9.38%2.29B | 18.69%2.05B |
Gross profit | -8.26%5.63B | -13.19%1.07B | -12.93%1.91B | 2.56%1.43B | -7.36%1.22B | -10.46%6.14B | -17.67%1.23B | -0.58%2.19B | -14.88%1.4B | -12.92%1.32B |
Operating expense | -4.47%5.41B | -10.16%1.32B | -9.34%1.31B | 4.01%1.48B | -1.93%1.31B | 2.55%5.67B | -2.73%1.47B | 1.62%1.45B | 9.85%1.42B | 2.45%1.33B |
Operating profit | -53.63%219.53M | -5.75%-247.87M | -19.92%595.89M | -100.90%-41.96M | -462.15%-86.53M | -64.44%473.47M | -2,082.97%-234.39M | -4.58%744.14M | -105.95%-20.89M | -107.27%-15.39M |
Net non-operating interest income (expenses) | 13.53%36.17M | -1.01%9.42M | 58.49%9.83M | -8.39%7.94M | 20.16%8.98M | 44.48%31.86M | 8.27%9.52M | -2.27%6.2M | 182.27%8.66M | 94.53%7.47M |
Non-operating interest income | 17.81%40.97M | 5.79%10.8M | 56.45%10.84M | -3.17%9.23M | 24.60%10.09M | 42.08%34.78M | 9.83%10.21M | -0.17%6.93M | 158.82%9.54M | 77.92%8.1M |
Non-operating interest expense | 64.43%4.8M | 99.13%1.38M | 39.06%1.01M | 48.74%1.3M | 77.27%1.12M | 20.30%2.92M | 36.96%693K | 22.18%727K | 41.79%872K | -11.66%629K |
Net investment income | -4.93%98.6M | -17.70%10.02M | 167.96%29.19M | -72.60%12.86M | -46.86%46.53M | 34.34%103.71M | -58.87%12.18M | -535.04%-42.96M | 336.26%46.93M | 224.82%87.56M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 143.54%883K | 105.51%243K | 3.29%596K | -125.46%-97K | -90.08%141K | -138.81%-2.03M | -239.23%-4.41M | -45.05%577K | -13.41%381K | 149.47%1.42M |
Less:Other special charges | -143.54%-883K | -105.51%-243K | -3.29%-596K | 125.46%97K | 90.08%-141K | 138.81%2.03M | 239.23%4.41M | 45.05%-577K | 13.41%-381K | -149.47%-1.42M |
Other non-operating income (expenses) | -41.08%-32.63M | -23.38%-17.41M | -98.55%132K | -15.24%-15.8M | 110.11%448K | -9.12%-23.13M | -21.95%-14.11M | 1,689.22%9.13M | -384.62%-13.71M | 39.32%-4.43M |
Income before tax | -44.76%322.55M | -6.22%-245.59M | -11.36%635.64M | -273.38%-37.06M | -139.72%-30.44M | -58.73%583.88M | -1,300.26%-231.21M | -10.10%717.09M | -94.10%21.38M | -67.50%76.63M |
Income tax | -50.42%110.06M | -22.09%-74.06M | -1.34%196.85M | -115.92%-7.28M | -114.53%-5.44M | -49.66%222M | -255.99%-60.67M | -19.45%199.52M | -49.05%45.74M | -42.13%37.4M |
Net income | -41.28%212.48M | -0.58%-171.53M | -15.22%438.79M | -22.22%-29.78M | -163.75%-25M | -62.84%361.88M | -768.87%-170.54M | -5.89%517.57M | -108.94%-24.37M | -77.08%39.22M |
Net income continuous operations | -41.28%212.48M | -0.58%-171.52M | -15.22%438.79M | -22.22%-29.78M | -163.75%-25M | -62.84%361.88M | -768.87%-170.54M | -5.89%517.57M | -108.94%-24.37M | -77.08%39.22M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -41.28%212.48M | -0.58%-171.53M | -15.22%438.79M | -22.22%-29.78M | -163.75%-25M | -62.84%361.88M | -768.87%-170.54M | -5.89%517.57M | -108.94%-24.37M | -77.08%39.22M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -41.28%212.48M | -0.58%-171.53M | -15.22%438.79M | -22.22%-29.78M | -163.75%-25M | -62.84%361.88M | -768.87%-170.54M | -5.89%517.57M | -108.94%-24.37M | -77.08%39.22M |
Gross dividend payment | ||||||||||
Basic earnings per share | -41.29%30.12 | -0.58%-24.32 | -15.21%62.21 | -22.61%-4.23 | -163.67%-3.54 | -62.84%51.3 | -766.67%-24.18 | -5.90%73.37 | -108.93%-3.45 | -77.08%5.56 |
Diluted earnings per share | -41.29%30.12 | -0.58%-24.32 | -15.22%62.2043 | -22.47%-4.23 | -163.67%-3.54 | -62.84%51.3 | -766.67%-24.18 | -5.89%73.37 | -108.94%-3.454 | -77.08%5.56 |
Dividend per share | 0.00%30 | 0.00%15 | 0 | 0.00%15 | 0 | 0.00%30 | 0.00%15 | 0 | 0.00%15 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |